财务数据和关键指标变化 - 公司2023年第一季度合并初步收入约为0.7百万美元,同比下降50% [25] - 剔除DetermaRx收入,持续经营业务相关的制药服务收入为0.3百万美元 [25] - 2023年第一季度成本收入约为0.8百万美元,主要来自诊断测试和为DetermaRx和制药服务客户提供的测试服务 [26] - 研发费用同比下降45%,从5.1百万美元降至2.8百万美元,主要由于CLIA实验室费用和重点产品开发支出的减少 [27] - 一般及行政费用同比下降34%,从5.7百万美元降至3.7百万美元,反映了管理层在2022年和2023年初控制与产品开发或商业活动无关的支出 [28] - 销售和营销费用同比下降63%,从3.2百万美元降至1.2百万美元,主要归因于DetermaRx产品开发和商业化工作的减少以及在2023年第一季度出售Razor Genomics [29] 各条业务线数据和关键指标变化 - DetermaIO RUO产品已完成第一阶段开发,正在优化测定以准备制造 [15] - DetermaIO在评估肿瘤微环境方面的优势在最近发表的一项临床研究中得到体现,结果显示DetermaIO可能比当前的标准生物标志物更好地识别对免疫检查点抑制剂治疗有反应的患者 [16] - DetermaCNI在转移性胰腺癌中的研究结果表明,该检测可以识别对治疗无反应的患者 [18][19] - 移植管理的VitaGraft检测正在通过CMS获得报销,试剂盒版本已完成第一阶段开发并正在准备制造,预计将于今年晚些时候进行早期市场准入 [20][21] 各个市场数据和关键指标变化 - 未提及具体市场数据和关键指标变化 公司战略和发展方向及行业竞争 - 公司正在转向高毛利可扩展的产品业务模式,而不是传统的服务实验室模式,这将使公司能够以较少的资本扩大收入 [10][11] - 公司正在整合实验室运营、精简产品组合并调整规模,以削减超过2000万美元的年度运营费用 [12][13] - 公司正在努力管理支出并向资本效率模式转型 [13] - 公司正在寻求外部合作伙伴和许可机会,以实现收入增长 [22] 管理层对经营环境和未来前景的评论 - 公司面临不利的市场环境,在第一季度集中精力控制成本并专注于投资是关键 [12] - 公司有信心实现未来的关键价值里程碑 [36] 问答环节重要的提问和回答 问题1 **Joseph Conway 提问** 询问DetermaIO和VitaGraft的里程碑时间表,包括首次获得报销决定和对收入产生重大贡献的时间 [45][46][47] **Josh Riggs 回答** 移植产品比DetermaIO提前约6个月获得报销决定,预计将首先获得报销 [46] DetermaIO作为一种独特的产品,MolDX将需要更多时间进行审查 [46] 公司希望能够在未来任何一个季度获得MolDX的报销决定 [46] 问题2 **Mason Carrico 提问** 询问DetermaIO的客户需求情况和潜在的关键风险 [55][58][59][60] **Josh Riggs 和 Anish John 回答** 公司在非小细胞肺癌PD-L1表达大于50%的人群中有最好的数据,这是一个需要决定是否加化疗的关键人群 [56] 公司也看到三阴性乳腺癌等其他适应症的需求,医生希望能够依赖一个可靠的检测来识别对抗PD-L1治疗有反应的患者 [57] 公司的现金流预测相对稳定,没有预见到会导致现金流出现大幅波动的未知因素 [59][60] 问题3 **Vidyun Bais 提问** 询问公司对移植领域的看法,以及关于潜在的试剂盒合作伙伴的进展情况 [65][67] **Josh Riggs 回答** 最近CMS对可报销项目的澄清可能影响了行业的整体收入,这也是公司希望开发RUO版本产品的原因,以开拓新的适应症并重新增加收入 [66] 公司正在与制造商和分销合作伙伴进行谈判,目标是在今年年底前推出产品,预计到第三季度将有更多清晰的商业策略 [68] 公司将采取轻资产的商业化模式,主要通过合作伙伴或分销渠道进行 [70]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to __________ Commission file number 1-37648 Oncocyte Corporation (Exact name of registrant as specified in its charter) California 27-1041563 (State or other jur ...

OncoCyte Corporation (NASDAQ:OCX) Q4 2022 Earnings Conference Call April 3, 2023 8:30 AM ET Company Participants Caroline Corner - Investor Relations, Westwicke Joshua Riggs - President and Chief Executive Officer Anish John - Chief Financial Officer Conference Call Participants Tyler Anderson - Piper Sandler Mark Massaro - BTIG Joseph Conway - Needham & Company Mason Carrico - Stephens Inc Bruce Jackson - The Benchmark Company David Westenberg - Piper Sandler Operator Good day and welcome to the OncoCyte ...

OncoCyte Corporation (NASDAQ:OCX) Q3 2022 Results Conference Call November 10, 2022 4:30 PM ET Company Participants Caroline Corner - Investor Relations Ronnie Andrews - President and Chief Executive Officer Anish John - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Mark Massaro - BTIG Thomas Flaten - Lake Street Mason Carrico - Stephens Bruce Jackson - Benchmark Company Operator Good day, and welcome to the OncoCyte Conference Call to discuss the Third Quarter 2022 F ...

OncoCyte Corporation (NASDAQ:OCX) Q2 2022 Earnings Conference Call August 10, 2022 4:30 PM ET Company Participants Caroline Corner - Westwicke, Investor Relations Ronnie Andrews - President and Chief Executive Officer Anish John - Chief Financial Officer Conference Call Participants David Westenberg - Piper Sandler Mike Mattson - Needham & Company Mason Carrico - Stephens Operator Good day, and welcome to the OncoCyte Conference Call to discuss the Second Quarter 2022 Financial Results. Today's call is bein ...

OncoCyte Corporation (NASDAQ:OCX) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Ronnie Andrews – President and Chief Executive Officer Mitch Levine – Chief Financial Officer Troy Williams – LifeSci Advisors Conference Call Participants Mike Matson – Needham & Company Mark Massaro – BTIG David Westenberg – Piper Sandler Paul Knight – KeyBanc Capital Markets Thomas Flaten – Lake Street Capital Markets Mason Carrico – Stephens Inc. Bruce Jackson – The Benchmark Company Operator ...

Q42021 Financial Results & Operating Highlights HONCOCYTE Where Tomorrow LIVES March 10, 2022 Forward Looking Statements Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to the anticipated revenue impact, value creation roadmap, expected market differentiatio ...

OncoCyte Corporation (NASDAQ:OCX) Q4 2021 Earnings Conference Call March 10, 2022 4:30 PM ET Company Participants Troy Williams - LifeSci Advisors Ronnie Andrews - President and Chief Executive Officer Mitch Levine - Chief Financial Officer Conference Call Participants Mark Massaro - BTIG Mike Matson - Needham & Company David Westenberg - Piper Sandler Mason Carrico - Stephens Paul Knight - KeyBanc Thomas Flaten - Lake Street Capital Markets Bruce Jackson - The Benchmark Company Operator Greetings. Welcome ...

OncoCyte Corporation (NASDAQ:OCX) Q3 2021 Earnings Conference Call November 9, 2021 4:30 PM ET Company Participants Bob Yedid – LifeSci Advisors, LLC Ronnie Andrews – President and Chief Executive Officer Mitch Levine – Chief Financial Officer Doug Ross – Chief Science Officer Padma Sundar – Chief Commercial Officer Conference Call Participants Paul Knight – KeyBanc Mark Massaro – BTIG Joseph Stringer – Needham Bruce Jackson – Benchmark Company Operator Greetings, and welcome to the Oncocyte Corporation Thi ...

Oncocyte Corporation (NASDAQ:OCX) Q2 2021 Earnings Conference Call August 10, 2021 4:30 PM ET Company Participants Bob Yedid - IR, LifeSci Advisors, LLC Ronnie Andrews - President and CEO Mitch Levine - CFO Padma Sundar - Chief Commercial Officer Conference Call Participants Mike Matson - Needham & Company Thomas Flaten - Lake Street Operator Greetings, and welcome to Oncocyte Corporation Second Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. A question-and-a ...